Cargando…
Therapeutic drug monitoring of amikacin in septic patients
INTRODUCTION: Use of higher than standard doses of amikacin (AMK) has been proposed during sepsis, especially to treat less susceptible bacterial strains. However, few data are available on drug concentrations during prolonged therapy and on potential adverse events related to this strategy. METHODS...
Autores principales: | Duszynska, Wieslawa, Taccone, Fabio Silvio, Hurkacz, Magdalena, Kowalska-Krochmal, Beata, Wiela-Hojeńska, Anna, Kübler, Andrzej |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4057344/ https://www.ncbi.nlm.nih.gov/pubmed/23886243 http://dx.doi.org/10.1186/cc12844 |
Ejemplares similares
-
Antibiotics and the Nervous System—Which Face of Antibiotic Therapy Is Real, Dr. Jekyll (Neurotoxicity) or Mr. Hyde (Neuroprotection)?
por: Hurkacz, Magdalena, et al.
Publicado: (2021) -
Influence of CYP2C19 Genotypes on the Occurrence of Adverse Drug Reactions of Voriconazole among Hematological Patients after Allo-HSCT
por: Sienkiewicz, Beata, et al.
Publicado: (2017) -
Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock
por: Taccone, Fabio Silvio, et al.
Publicado: (2010) -
Comparison of clinical pharmacology of voriconazole and posaconazole
por: Sienkiewicz, Beata M., et al.
Publicado: (2016) -
Therapeutic Drug Monitoring of Amikacin in Neutropenic Oncology Patients
por: Aquino, Maria, et al.
Publicado: (2023)